JPMorgan Chase & Co. Cuts Stock Position in Sana Biotechnology, Inc. (NASDAQ:SANA)

JPMorgan Chase & Co. cut its position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 3.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 917,173 shares of the company’s stock after selling 34,391 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.41% of Sana Biotechnology worth $3,815,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of SANA. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Sana Biotechnology by 17.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 35,196 shares of the company’s stock valued at $146,000 after acquiring an additional 5,338 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Sana Biotechnology by 2.8% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 253,899 shares of the company’s stock worth $1,056,000 after purchasing an additional 6,823 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in Sana Biotechnology in the 3rd quarter worth $29,000. Stifel Financial Corp bought a new stake in Sana Biotechnology in the third quarter worth $43,000. Finally, EP Wealth Advisors LLC purchased a new stake in Sana Biotechnology during the third quarter valued at about $45,000. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Stock Performance

Shares of SANA stock opened at $3.16 on Friday. Sana Biotechnology, Inc. has a fifty-two week low of $1.52 and a fifty-two week high of $12.00. The firm has a market cap of $705.53 million, a P/E ratio of -2.26 and a beta of 1.45. The business’s 50 day moving average price is $2.42 and its 200-day moving average price is $3.98.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. As a group, equities analysts predict that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.

Insider Buying and Selling

In related news, insider Fmr Llc sold 290,912 shares of Sana Biotechnology stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the completion of the transaction, the insider now directly owns 4,541,511 shares of the company’s stock, valued at $29,474,406.39. This trade represents a 6.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 31.10% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms have recently weighed in on SANA. JMP Securities lowered Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th. TD Cowen upgraded Sana Biotechnology from a “hold” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, HC Wainwright raised their target price on shares of Sana Biotechnology from $8.00 to $11.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $14.25.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.